TRV045

TRV045 (CAS 2256030-24-5) is a novel, orally bioavailable, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) agonist under clinical development by Trevena, Inc. as a potential non-opioid treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy and, through a collaboration with the National Institutes of Health, as a potential treatment for epilepsy. The compound is distinguished from the approved S1P receptor modulator class (fingolimod, siponimod, ozanimod, ponesimod) by a pharmacological mechanism that produces sustained S1P1R agonism without the receptor internalization, functional desensitization, or S1P1R protein downregulation that characterizes fingolimod and related agents. The practical consequence of this mechanistic differentiation is the absence of peripheral lymphocyte sequestration (lymphopenia), the absence of first-dose bradycardia and atrioventricular conduction delay, and the absence of the immunosuppressive liability that defines the approved S1P modulator class and limits its application outside multiple sclerosis. In preclinical models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy (CIPN), oral TRV045 at 1 to 10 mg/kg produced dose-dependent reversal of mechanical allodynia, cold allodynia, and thermal hyperalgesia. Effects were sustained over 14 days of repeated dosing without evidence of tolerance, receptor desensitization, or S1P1R protein reduction in spinal cord tissue. In contrast, fingolimod in the same CIPN model produced approximately 70 percent reduction in S1P1R functional activity and 30 percent protein reduction. At higher doses (100 mg/kg) in a prevention paradigm, TRV045 reduced both mechanical and cold hypersensitivity 24 hours after the final dose, with cold hypersensitivity reduction persisting seven days after treatment cessation, suggesting potential disease-modifying activity. In epilepsy models conducted through the NIH-supported Epilepsy Therapy Screening Program (ETSP), TRV045 at 30 mg/kg significantly increased time to myoclonic twitch in the pentylenetetrazol seizure threshold test and produced dose-dependent protection in the maximal electroshock seizure test with an ED50 of 18 mg/kg in rats. In human Phase 1 clinical studies, TRV045 has been evaluated in three completed trials comprising a first-in-human single and multiple ascending dose study in 89 healthy volunteers, a target engagement proof-of-concept study using the capsaicin-induced pain (PainCart) model in 25 healthy subjects, and a transcranial magnetic stimulation (TMS) and electroencephalography (EEG) proof-of-concept study in 25 healthy male subjects. The target engagement study demonstrated statistically significant, dose-dependent reduction in capsaicin-induced mechanical allodynia at 150 mg and 300 mg single doses compared to placebo. The TMS/EEG study demonstrated statistically significant increases in alpha, beta, and gamma frequency band power spectral density after four days of 250 mg daily dosing, consistent with central nervous system target engagement and modulation of cortical excitability. Across all three completed Phase 1 studies, TRV045 demonstrated a favorable tolerability profile with no serious adverse events, no drug-related discontinuations, no clinically significant lymphopenia, no bradycardia, no blood pressure changes, and no prolongation of QTcF or PR intervals. The most common adverse events were mild headache, somnolence, dizziness, and fatigue. Trevena is advancing an optimized oral formulation through clinical pharmacokinetic evaluation in preparation for Phase 2 development. TRV045 is an investigational compound not approved by the United States Food and Drug Administration. This monograph reviews the chemistry and identification of TRV045; the S1P1R agonist mechanism of action and its differentiation from functional antagonist S1P modulators; the preclinical pharmacology in neuropathic pain and epilepsy models; the Phase 1 clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interaction considerations; adverse events and safety; and a comparative assessment of five S1P receptor modulators (fingolimod, siponimod, ozanimod, ponesimod, amiselimod) against TRV045 on five competency standards.